Plendil Related Published Studies
Well-designed clinical trials related to Plendil (Felodipine)
The calcium channel blocker felodipine attenuates the positive hemodynamic effects of the beta-blocker metoprolol in severe dilated cardiomyopathy--a prospective, randomized, double-blind and placebo-controlled study with invasive hemodynamic assessment. [2009.02.20]
Comparative study of barnidipine and felodipine in Chinese patients with essential hypertension. [2006.07]
A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. [2006.05]
A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT). [2006.04]
Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients: amlodipine versus felodipine extended release. [2006.01]
The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. [2005.12]
Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction. [2005.10]
Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. [2005.03]
Effect of menthol on the pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. [2005.01]
Urinary excretion of aquaporin-2 after furosemide and felodipine in healthy humans. [2005]
Well-designed clinical trials possibly related to Plendil (Felodipine)
Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination. [2008.12]
Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. [2008.04]
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. [2007.04.17]
Lercanidipine in the treatment of hypertension. [2007.03]
Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. [2006.10]
Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy. [2006.04]
Initiation of hypertension treatment with a fixed-dose combination or its monocomponents -- does it really matter? [2006.03]
Cost implications of development of diabetes in the ALPINE study. [2006.03]
AT1 receptor antagonism improves endothelial dysfunction in postmenopausal women. [2006.01.20]
Impact of the intragastric location of extended release tablets on food interactions. [2005.11.28]
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. [2005.03.12]
Other research related to Plendil (Felodipine)
Felodipine downregulates serum interleukin-18 levels in rats with fructose-induced metabolic syndrome. [2009.04]
Pair distribution function X-ray analysis explains dissolution characteristics of felodipine melt extrusion products. [2009.04]
Extended release felodipine self-nanoemulsifying system. [2009]
[Curative effects on mild to moderate primary hypertension and influence on pulse wave velocity of slow releasing felodipine] [2008.11.18]
Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. [2008.10]
Effect of poloxamer on the dissolution of felodipine and preparation of controlled release matrix tablets containing felodipine. [2008.08]
Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats. [2008.07]
The calcium channel blocker felodipine attenuates the positive hemodynamic effects of the beta-blocker metoprolol in severe dilated cardiomyopathy - A prospective, randomized, double-blind and placebo-controlled study with invasive hemodynamic assessment. [2008.06.24]
The calcium channel blocker felodipine attenuates the positive hemodynamic effects of the beta-blocker metoprolol in severe dilated cardiomyopathy - A prospective, randomized, double-blind and placebo-controlled study with invasive hemodynamic assessment. [2008.06.23]
Effect and tolerability of felodipine ER (Feloten) in the treatment of hypertension assessed by office blood pressure and home blood pressure. [2008.05]
Molecular mechanisms of felodipine suppressing atherosclerosis in high-cholesterol-diet apolipoprotein e-knockout mice. [2008.02]
Effects of extended-release felodipine on endothelial vasoactive substances in patients with essential hypertension. [2008]
[Efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination therapy in the treatment of mild to moderate essential hypertension in China.] [2007.12.18]
[Preparation of transdermal drug delivery system of felodipine-metoprolol and its bioavailability in rabbits] [2007.11]
Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. [2007.08]
[The FEVER (Felodipine EVEnt Reduction) trial; a randomised, double-blind, placebo-controlled trial in Chinese hypertensive patients] [2007.01]
Comparison in vitro felodipine release rate from the original versus generic product with controlled release of the drug. [2007]
Dihydropyridines, felodipine, and PHARMAC. [2005.07.15]
Felodipine-influenced gingival enlargement in an uncontrolled type 2 diabetic patient. [2005.07]
Desmopressin: in adults with nocturia. [2005]
Other possibly related research studies
Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. [2006]
[Evidence-based therapy of Raynaud's syndrome.] [2006.07]
[Grouping-related bias of effects of the same anti-hypertensive drugs in non-doubleblind randomized trials: a meta-analysis in Chinese hypertension clinical literature] [2006.05]
CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. [2006.04]
Drug-associated gingival enlargement: case report and review of aetiology, management and evidence-based outcomes of treatment. [2005]
[Toxicological analysis of selected 1,4-dihydropyridine calcium channel blockers in the diagnosis of intoxications] [2005.01]
Retrospective evaluation of a possible interaction between warfarin and levofloxacin. [2005.01]
Hypertension, possible vascular protection and lercanidipine. [2006.11]
Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs. [2006.11]
Interaction of grapefruit juice and calcium channel blockers. [2006.07]
Asymmetric membrane capsules for delivery of poorly water-soluble drugs by osmotic effects. [2005.06.13]
Pharmacologic treatment of chronic pediatric hypertension. [2005]
Pharmacologic agents in the management of hypertension--nisoldipine coat-core. [2007.04]
A review of calcium channel antagonists in the treatment of pediatric hypertension. [2006]
Olmesartan medoxomil: current status of its use in monotherapy. [2006]
Determination of gambogic acid in dog plasma by high-performance liquid chromatography for a pharmacokinetic study. [2007.03]
Risk and predictability of drug interactions in the elderly. [2007]
Estimation of intragastric solubility of drugs: in what medium? [2007.05]
Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. [2007.06]
The effect of ionizing radiation of 1,4-dihydropyridine derivatives in the solid state. [2007.05]
Determination and pharmacokinetics of manidipine in human plasma by HPLC/ESIMS. [2007.08]
Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. [2007.10]
The influence of hydro-alcoholic media on hypromellose matrix systems. [2007.10]
A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. [2008.03]
Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells. [2008.02.03]
Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. [2008.03]
The application of glucose biosensor in studying the effects of insulin and anti-hypertensive drugs towards glucose level in brain striatum. [2008.07.15]
Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. [2008.05]
Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. [2009.08]
Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens. [2009.08]
Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics. [2009.07]
[Serum uric acid prevalence and changes post various antihypertensive agents in patients with essential hypertension] [2008.06]
Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination. [2008]
|
